| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Alternative Names | WDR45, WD Repeat Domain 45, WIPI4, WIPI-4, WD Repeat Domain Phosphoinositide-Interacting Protein 4, WD Repeat-Containing Protein 45, WD Repeat Domain X-Linked 1, WDRX1, WDRXI4, JM5, NBIA4, NBIA5, WD45 Repeat Protein Interacting With Phosphoinositides, Progranulin-Associated Neurodegeneration Protein, MGC163339, MGC163341 |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Gene ID | |
| Host | |
| Immunogen | Synthetic peptide from the C-terminal of Human WIPI4 (aa. 312-322) |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
WDR45, also known as WIPI-4, is a 360-amino acid protein containing WD40 repeats, which are structural motifs involved in protein-protein interactions. As a member of the WIPI (WD repeat domain phosphoinositide-interacting) protein family, WDR45 plays a critical role in autophagy—a cellular degradation and recycling process essential for neuronal health and homeostasis.
WDR45 exists in three alternatively spliced isoforms and is ubiquitously expressed, with highest levels in heart and skeletal muscle. In the nervous system, WDR45 is vital for maintaining cellular quality control, particularly in long-lived neurons that are highly susceptible to proteotoxic stress. Dysfunction in WDR45-mediated autophagy has been directly linked to neurodegeneration with brain iron accumulation (NBIA), specifically types 4 and 5, which are characterized by progressive cognitive decline, motor dysfunction, and iron deposition in the basal ganglia.
Mutations in the WDR45 gene disrupt autophagosome formation and trafficking, leading to the accumulation of damaged proteins and organelles—a hallmark of many neurodegenerative diseases, including Parkinson’s and Alzheimer’s. As such, WDR45 is increasingly recognized as a potential biomarker and therapeutic target in neurodegenerative disease research.
Understanding the molecular mechanisms of WDR45 offers valuable insights into the intersection of autophagy, iron metabolism, and neuronal survival.
A 1:1000 dilution of SPC-651 was sufficient for detection of WIPI4 in 15 µg of Human HeLa Cell Lysates by ECL immunoblot analysis using goat anti-rabbit IgG:HRP as the secondary antibody.
Cite this product varies by variant:
- SPC-651D — Size: 100 ug: WDR45 Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-651D, RRID: AB_2705375)
- SPC-651D-A390 — Size: 100 ug: WDR45 Antibody: ATTO 390 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-651D-A390, RRID: AB_2705376)
- SPC-651D-A488 — Size: 100 ug: WDR45 Antibody: ATTO 488 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-651D-A488, RRID: AB_2705377)
- SPC-651D-A594 — Size: 100 ug: WDR45 Antibody: ATTO 594 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-651D-A594, RRID: AB_2705379)
- SPC-651D-APC — Size: 100 ug: WDR45 Antibody: APC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-651D-APC, RRID: AB_2705385)
- SPC-651D-BI — Size: 100 ug: WDR45 Antibody: Biotin (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-651D-BI, RRID: AB_2705386)
- SPC-651D-FITC — Size: 100 ug: WDR45 Antibody: FITC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-651D-FITC, RRID: AB_2705387)
- SPC-651D-HRP — Size: 100 ug: WDR45 Antibody: HRP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-651D-HRP, RRID: AB_2705388)
- SPC-651D-PCP — Size: 100 ug: WDR45 Antibody: PerCP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-651D-PCP, RRID: AB_2705390)
- SPC-651D-RPE — Size: 100 ug: WDR45 Antibody: RPE (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-651D-RPE, RRID: AB_2705391)
- SPC-651S — Size: 12 ug: WDR45 Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-651S, RRID: AB_2705375)
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
3. Haack T.B., et al. (2012) Am J Hum Genet. 91(6): 1144–1149.